NON-INVASIVE PRENATAL TESTING (NIPT) MARKET ANALYSIS

Non-invasive Prenatal Testing (NIPT) Market, by Test Type (Panel 1 Test, Panel 2 Test, and Panel 3 Test), by Application (Trisomy, Microdeletion Syndrome, Sex chromosomes abnormalities, and Others), by End User (Hospitals, Diagnostic Laboratories, and Maternity Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Oct 2022
Code : CMI579
Pages :145
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Non-invasive Prenatal Testing (NIPT) MarketSize and Trends

Global non-invasive prenatal testing market is estimated to be valued at US$ 1,350.9 million in 2022 and is expected to exhibit a CAGR of 18.5% during the forecast period (2022-2030).

High prevalence of chromosomal disorders is expected to propel growth of the global non-invasive prenatal testing market over the forecast period. For instance, in February 2020, a paper was published by National Center for Biotechnology Information according to the which, down syndrome is the most common genomic disorder occurs in the neonatal and is caused by trisomy of Homo sapiens chromosome 21 (HSA21). The prevalence of down syndrome is increasing substantially as the global population is growing. For example, prevalence of down syndrome in USA from year 1950- 2013 is increased from 50,000 to 212,000 respectively.

Increasing launches and approvals of new non-invasive prenatal tests (NIPT) along with increasing prevalence of chromosomal disorders is expected to propel the market growth during the forecasted period.